Stroma AReactive Invasion Front Areas (SARIFA), tumour immune microenvironment, and survival in colorectal cancer
Tapiainen, Vilja V.; Sirniö, Päivi; Elomaa, Hanna; Karjalainen, Henna; Äijälä, Ville K.; Kastinen, Meeri; Kehusmaa, Akseli; Pohjanen, Vesa Matti; Lindgren, Outi; Sirkiä, Onni; Ahtiainen, Maarit; Helminen, Olli; Wirta, Erkki Ville; Rintala, Jukka; Saarnio, Juha; Rautio, Tero; Seppälä, Toni T.; Böhm, Jan; Mecklin, Jukka Pekka; Tuomisto, Anne; Mäkinen, Markus J.; Väyrynen, Juha P. (2025)
Tapiainen, Vilja V.
Sirniö, Päivi
Elomaa, Hanna
Karjalainen, Henna
Äijälä, Ville K.
Kastinen, Meeri
Kehusmaa, Akseli
Pohjanen, Vesa Matti
Lindgren, Outi
Sirkiä, Onni
Ahtiainen, Maarit
Helminen, Olli
Wirta, Erkki Ville
Rintala, Jukka
Saarnio, Juha
Rautio, Tero
Seppälä, Toni T.
Böhm, Jan
Mecklin, Jukka Pekka
Tuomisto, Anne
Mäkinen, Markus J.
Väyrynen, Juha P.
2025
British Journal of Cancer
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-202505155523
https://urn.fi/URN:NBN:fi:tuni-202505155523
Kuvaus
Peer reviewed
Tiivistelmä
Background: SARIFA (Stroma AReactive Invasion Front Areas), defined as the direct contact between a tumour cell cluster and adipose cells at the invasion margin, has been proposed as a prognostic marker in gastrointestinal cancers. We hypothesized that SARIFA is associated with an immunosuppressive tumour microenvironment. Methods: SARIFA status was evaluated in two large colorectal cancer cohorts (N = 1876). Survival analyses were performed using multivariable Cox regression. Immune cell densities were analysed utilizing multiplex and conventional immunohistochemistry combined with digital image analysis. Results: SARIFA-positivity was independently associated with a shorter cancer-specific survival in both cohorts [Cohort 1: hazard ratio (HR) for SARIFA-positive (vs. negative) 1.75 (95% CI 1.35–2.25), P < 0.0001; Cohort 2: HR for SARIFA-positive (vs. negative) 2.09 (95% CI 1.43–3.05), P = 0.0001]. SARIFA-positivity was associated with lower densities of CD3+ T cells, CD66b+ granulocytes, M1-like macrophages, and CD14+HLA-DR+ mature monocytic cells, but higher densities of M2-like macrophages and CD14+HLA-DR- immature monocytic cells. Mean Cohen’s kappa for SARIFA evaluation between eight investigators was 0.80. Conclusions: SARIFA status is a highly reproducible, independent prognostic factor in colorectal cancer. SARIFA-positivity is associated with lower densities of antitumourigenic immune cells and the polarisation of macrophages towards a protumourigenic M2-like phenotype.
Kokoelmat
- TUNICRIS-julkaisut [20583]